Davion Healthcare Plc (: DAVI)

Davion Healthcare Plc designs, develops, and patents non-invasive home medical tests for early detection and monitoring of health anomalies. The company operates under a licensing-based commercialization model where it grants manufacturing, marketing, sales, and distribution rights to regional or global commercial partners. Its products are intended for over-the-counter sale directly to consumers without healthcare professional involvement, subject to regulatory compliance in each jurisdiction.

The company generates revenue primarily through upfront or periodic licensing fees and ongoing royalty payments tied to product sales by licensees. Revenue is recognized upon satisfaction of performance obligations under licensing agreements, including milestone-based fees and recurring royalties calculated as a percentage of gross or net sales or on a per-unit basis. As of the filing date, Davion Healthcare Plc has a global manufacturing and distribution license agreement with NeuRX Health, Inc. for its BreastCheck product, providing for $120 million in staged license fee payments and minimum annual royalties of $10 million over an initial ten-year term.

The company operates through the following segments:

• BreastCheck: This segment focuses on the design, development, and commercialization of a non-invasive home test for early detection of abnormal breast tissue patterns. The product uses thermochromic liquid crystal film to measure and map skin surface temperature variations, producing a thermal map that highlights potential concerns. BreastCheck is registered as a Class I medical device in the United States under group registration number 3027486037 and is eligible for over-the-counter sale in pharmacies and online without a prescription.

• FootFlow: This segment provides a non-invasive home test for monitoring diabetic circulation in the feet and hands, as well as peripheral arterial disease. The test compares skin temperature between toes on each foot to detect early signs of impaired blood flow or inflammation. FootFlow shares the same FDA group registration number as BreastCheck and is also registered as a Class I medical device for over-the-counter sales.

• Testic: This segment is dedicated to a non-invasive home test for testicular health monitoring, leveraging the same thermographic technology platform as BreastCheck and FootFlow. The product is intended for over-the-counter consumer use and requires only a manufacturer’s self-declaration of conformity and registration for Class I medical devices prior to commercial launch in any country.

• ThermaDerm: This segment covers a non-invasive home test for skin health and wound monitoring, utilizing localized temperature changes to track inflammation or healing progress. Like Testic, ThermaDerm does not require premarket regulatory approval beyond the standard Class I medical device self-declaration and notification process in each target country.

Davion Healthcare Plc holds a competitive advantage through its proprietary thermographic technology platform, which combines liquid crystal film with AI-enabled image analysis to deliver standardized, reproducible health insights. The company states that, to date, there are no other known competitors attempting to utilize similar technologies for non-invasive home medical testing, giving it a first-mover advantage in this niche. Its intellectual property portfolio includes issued patents and pending applications across the UK, USA, and PCT jurisdictions, with expiration dates extending to 2044, providing long-term protection for its core innovations in breast, foot, testicular, and skin health monitoring.

The company serves individual consumers seeking convenient, at-home health monitoring solutions for conditions such as breast abnormalities, diabetic circulation issues, testicular health concerns, and skin inflammation or wound healing. Its products are designed for direct-to-consumer sale through pharmacies, online platforms, and other retail channels without requiring a prescription or healthcare professional supervision, subject to local regulatory compliance for over-the-counter Class I medical devices.